Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency

Julie Høgh1, Malene Hove-Skovsgaard1, Marco Gelpi1, Anne Marie Reimer Jensen1, Jan Gerstoft1,2, Thomas Benfield2,3, Heidi Storgaard4 and Susanne Dam Nielsen1,2*

Abstract
Background: As people living with HIV (PLWH) are growing older, there is increased incidence of metabolic diseases, including type 2 diabetes mellitus, for which insulin resistance is a key determinant. In this study, we aimed to investigate risk factors associated with insulin resistance in PLWH.

Methods: We included well-treated PLWH without hepatitis co-infection, and with available fasting serum insulin and plasma glucose (n = 643) from the Copenhagen Comorbidity in HIV Infection Study. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR). We investigated the association between risk factors and high HOMA-IR in a logistic regression model adjusted for age, sex, abdominal obesity, smoking status, and origin. When including use of thymidine analogues and/or didanosine in the model, we also adjusted for time with HIV.

Results: Median (IQR) age of PLWH was 52 years (46–61), and 87% (n = 557) were male. Median (IQR) HOMA-IR was 1.86 (1.23–3.14) mmol/L × mU/L. Risk factors significantly associated with high HOMA-IR included older age, BMI ≥ 25, abdominal obesity, waist circumference, use of thymidine analogues and/or didanosine, time with HIV, and CD4+ nadir < 200 cells/µL.

Conclusions: Insulin resistance in PLWH is associated with both use of thymidine analogues and/or didanosine and prior immunodeficiency suggesting that increased attention on blood glucose in these patients could be beneficial.

Keywords: HIV-infection, Diabetes, Insulin resistance, Comorbidity, Antiretroviral therapy

Background
The population of people living with HIV (PLWH) is growing older [1], and, accordingly, there is an increasing incidence of age-related non-AIDS comorbidities including diabetes mellitus type 2 (T2DM) [2–5]. Insulin resistance is a key determinant of T2DM and has previously been associated with age, overweight, and obesity [6]. Especially, abdominal obesity is thought to be associated with a high risk of developing insulin resistance [7, 8]. In PLWH, exposure to older generation antiretroviral therapy (ART) has been associated with both the development of T2DM and long-lasting alterations of body fat from subcutaneous adipose tissue to visceral adipose tissue [9–12].
In this study, we determined insulin resistance in PLWH and aimed to investigate traditional and HIV-specific risk factors associated with insulin resistance. Additionally, we investigated the potential effect modification of prior exposure to older generation ART defined as previous use of thymidine analogues and/or didanosine.

**Methods**

**Study population and demographics**
The Copenhagen Comorbidity in HIV Infection (COCOMO) Study is a non-interventional cohort study that included PLWH from the greater Copenhagen area. Inclusion criteria were a positive HIV test and age > 18 years. The procedures for recruitment and data collection have been described in detail elsewhere [13]. Inclusion and baseline examinations took place from March 2015 to December 2016 where 1099 participants were included. Of these, 949 participants participated in the 2-year-follow-up examination which took place from April 2017 to April 2019. In the present study, we included participants at the 2-year-follow-up examinations with available fasting serum insulin and plasma glucose, current treatment with ART and HIV RNA < 50 copies/mL, and absence of co-infection with hepatitis B and C. In total 643 participants were included in the present study.

Hepatitis B virus co-infection was defined as positive hepatitis B virus surface antigen. Hepatitis C virus co-infection was defined as positive hepatitis C virus RNA.

Ethical approval was obtained by the Regional Ethics Committee of Copenhagen (H-8-2014-004). Written informed consent was obtained from all participants.

At the 2-year-follow-up, a physical exam including anthropometrics and blood pressure was performed by trained clinical staff according to epidemiologic research standards [14, 15]. Questionnaires were used to collect information regarding smoking, origin, and antihypertensive treatment. Fasting blood samples were collected and serum insulin, plasma glucose, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and total cholesterol were measured. Fasting blood samples were collected after ≥ 8 h of fasting. Data regarding HIV infection were obtained from a review of medical charts. Exposure to older generation ART was defined as ever use of thymidine analogues (zidovudine and stavudine) and/or didanosine. Duration of ART was defined as time since initiation of treatment with ART. Well-treated was defined as current treatment with ART and HIV RNA < 50 copies/mL.

**Definition of clinical outcomes**
In accordance with the original homeostasis model assessment (HOMA), insulin resistance was calculated using the equation: fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L)/22.5 [16]. Due to the lack of standardized cut-off value for insulin resistance [17], we defined high insulin resistance (high HOMA-IR) as the upper quartile of the HOMA insulin resistance index.

According to WHO guidelines, abdominal obesity was defined as waist-to-hip ratio (WHR) ≥ 0.9 for men and ≥ 0.85 for women and BMI was classified as < 18.5 underweight, 18.5–24.99 normal weight, 25–29.99 overweight, and ≥ 30 kg/m² obese [18]. According to the questionnaires smoking status was defined as either current smoker, previous smoker or never smoker.

**Statistics**
We reported frequency counts and percentages for categorical data and continuous data with means and standard deviations for normal deviates and medians with interquartile ranges (IQR) for variables not normally distributed.

We investigated the association between high HOMA-IR and traditional and HIV-specific risk factors using a logistic regression model adjusted for age, sex, BMI category, smoking status (previous/current/never smoker), and origin. Traditional risk factors were included in the adjusted model. Additionally, we tested the association between abdominal obesity and insulin resistance by adding abdominal obesity to the predefined model. Furthermore, HIV-specific risk factors (Current CD4⁺ count per 100 cells/µL, CD4⁺/CD8⁺-ratio, CD4⁺ nadir < 200 cells/µL, prior exposure to older generation ART, duration of treatment with ART and previous AIDS-defining conditions) were investigated by adding them to the model one at a time. When including exposure to older generation ART and duration of ART in the model, we also adjusted for time with HIV.

A possible effect modification by prior exposure to older generation ART on the association between significant risk factors and high HOMA-IR was explored by adding an interaction term to the model.

In an exploratory analysis using our predefined model we investigated the association between high HOMA-IR and hip measurements and waist measurements tested separately. Additionally, we tested the association between time with HIV and high HOMA-IR using our predefined model.

A P-value of < 0.05 was considered statistically significant. All P-values were two-sided.

**Results**
Among the included participants, the median (IQR) age was 52 years (46–61), 87% (n = 557) were male, and 52% (n = 337) had prior exposure to older generation...
ART, Table 1. Median [IQR] index of IR was 1.86 [1.23–3.14] mmol/L × mU/L.

Traditional risk factors associated with high HOMA-IR
Traditional risk factors significantly associated with high HOMA-IR included age (adjusted OR [aOR] = 1.57, per decade older, [95% CI 1.29–1.90], P < 0.001), BMI 25–29.9 (aOR = 2.69 [1.73–4.18], compared to BMI 20–24.9, P < 0.001), BMI ≥ 30 (aOR = 12.43 [6.81–22.67], compared to BMI 20–24.9, P < 0.001) and abdominal obesity (aOR = 4.93 [2.80–8.68], P < 0.001), Fig. 1. Other traditional risk factors such as smoking status, origin, and sex were not associated with high HOMA-IR, Table 2. Furthermore, we found waist measurements to be associated with high HOMA-IR (aOR = 1.11, per cm, [1.07;1.14], P < 0.001), while hip measurements were not (aOR = 1.01, per cm, [0.97;1.04], P = 0.768).

HIV-specific risk factors associated with high HOMA-IR
Exposure to older generation ART (aOR = 2.14 [1.24–3.71], P = 0.006), and nadir CD4+ < 200 cells/µL (aOR = 1.56 [1.02–2.38], P = 0.038) were significantly associated with high HOMA-IR, Fig. 1. Current CD4+ count per 100 cells/µL, CD4+/CD8+-ratio, duration of ART and previous AIDS defining condition were not associated with high HOMA-IR, Table 2. In exploratory analysis we found time with HIV to be associated with high HOMA-IR (aOR = 1.19, per 5 years, [1.04–1.35], P = 0.009).

Effect modification by prior exposure to older generation ART
When investigating effect modification by prior exposure to older generation ART, we found the association between abdominal obesity and high HOMA-IR to be stronger in PLWH with prior exposure to older generation ART (aOR = 8.08 [3.25–20.12] vs aOR = 2.68 [1.20–5.97], P-interaction = 0.042), Fig. 1. We found no effect modification between older generation ART and other risk factors.

Discussion
In this study of well-treated PLWH, abdominal obesity, BMI ≥ 25, exposure to older generation ART, and CD4+ nadir < 200 cells/µL was associated with insulin resistance. Furthermore, the association between abdominal obesity and insulin resistance was stronger in PLWH with previous use of older generation ART. This suggests that insulin resistance in PLWH is related to both exposure to older generation ART and prior immunodeficiency.

Insulin resistance is a key determinant in the development of T2DM [19]. In the COCOMO study, we have previously reported an 1.7 increased odds of T2DM in PLWH compared to uninfected individuals [4]. This finding is consistent with findings from other countries [2, 3]. In this study, among the traditional risk factors, age, BMI ≥ 25 and abdominal obesity was associated with insulin resistance in PLWH. These are all well-described risk factors for both insulin resistance and T2DM [6]. Especially, abdominal obesity, including increased amounts of visceral fat, is thought to be associated with a high risk of developing insulin resistance [7, 8].

Among HIV-specific risk factors, exposure to older generation ART was associated with insulin resistance, even when adjusting for time with HIV. This is consistent with other studies associating exposure to older generation ART and T2DM [9, 10]. In muscle and adipose tissue

### Table 1
Clinical and demographic characteristics of the study population

| Variable                          | PLWH (n = 643) |
|-----------------------------------|----------------|
| Age, years, median (IQR)          | 52 (46, 61)    |
| Sex (male), n (%)                 | 557 (87)       |
| Scandinavian or other European origin, n (%) | 562 (87) |
| BMI (kg/m²), median (IQR)         | 25 (23, 27)    |
| Underweight, BMI < 18.5, n (%)    | 13 (2)         |
| Normal weight, BMI 18.5–24.9, n (%) | 319 (50)     |
| Overweight, BMI25–29.9, n (%)     | 234 (36)       |
| Obese, BMI ≥ 30, n (%)            | 77 (12)        |
| Abdominal obesity, n (%)          | 372 (58)       |
| Smoking status                    |                |
| Current, n (%)                    | 154 (24)       |
| Previous, n (%)                   | 218 (34)       |
| Never, n (%)                      | 266 (41)       |
| Hypertension, yes, n (%)          | 317 (49)       |
| Transmission mode                 |                |
| MSM, n (%)                        | 461 (72)       |
| Heterosexual, n (%)               | 140 (22)       |
| IDU, n (%)                        | 5 (0.8)        |
| Other, n (%)                      | 10 (1.6)       |
| Current CD4+, cells/µL, median (IQR)| 660 (515, 831) |
| < 200                             | 10 (1.6)       |
| 200–349                           | 25 (4)         |
| 350–499                           | 101 (16)       |
| ≥ 500                             | 467 (73)       |
| CD4+/CD8+ ratio, median (IQR)     | 0.9 (0.6, 1.2) |
| Time since HIV diagnosis, years, median (IQR) | 16 (9, 24) |
| History of AIDS (yes), n (%)      | 111 (17)       |
| Time with ART treatment, years, median (IQR) | 13 (7, 20) |
| Exposure to older generation ART, yes, n (%) | 337 (52)     |

Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or antihypertensive treatment

MSM: men who have sex with men; IDU: injecting drug use; ART: combined antiretroviral therapy
older generation ART has been shown to inhibit glucose transporter 4 (GLUT4) [5, 20, 21] that contributes to glucose homeostasis. Accordingly, inhibition of GLUT4 may lead to insulin resistance which may explain the association between older generation ART and insulin resistance. Furthermore, older generation ART has been associated with changes in adipose tissue including lipodystrophy [11, 12]. Interestingly, the association between

---

![Figure 1](image)

**Fig. 1** Adjusted OR calculated using a logistic regression model adjusted for age, sex, BMI, smoking status, and origin. When including exposure to older generation ART in the model we also adjusted for time with HIV.

---

**Table 2** Risk factors associated with high HOMA-IR

| Traditional risk factors | OR [95% CI] | P-value | aOR [95% CI] | P-value |
|--------------------------|------------|---------|--------------|---------|
| Age, per 10 years older  | 1.45 [1.22–1.69] | <0.001 | 1.57 [1.29–1.90] | <0.001 |
| Male sex                 | 0.86 [0.52–1.43] | 0.556 | 1.04 [0.57–1.90] | 0.894 |
| Abdominal obesity        | 7.34 [4.49–12.00] | <0.001 | 4.93 [2.80–8.68] | <0.001 |
| Waist circumference, per cm | 1.10 [1.08–1.13] | <0.001 | 1.11 [1.07–1.14] | <0.001 |
| Hip circumference, per cm | 1.08 [1.05–1.10] | <0.001 | 1.01 [0.97–1.04] | 0.768 |
| BMI                      | Ref         | Ref     | Ref          | Ref     |
| Normal weight, BMI 18.5–24.99 | Ref    | Ref | Ref | Ref |
| Overweight, BMI 25–29.99 | 2.56 [1.67–3.91] | <0.001 | 2.69 [1.73–4.18] | <0.001 |
| Obese, BMI ≥ 30          | 10.53 [6.06–18.31] | <0.001 | 12.43 [6.81–22.67] | <0.001 |
| Smoking                  | Ref         | Ref     | Ref          | Ref     |
| Never smoker             | Ref         | Ref     | Ref          | Ref     |
| Current smoker           | 0.84 [0.52–1.34] | 0.453 | 1.29 [0.76–2.19] | 0.347 |
| Previous smoking         | 1.19 [0.79–1.78] | 0.405 | 1.10 [0.69–1.74] | 0.686 |
| Non-European origin      | 1.16 [0.67–2.01] | 0.598 | 1.25 [0.65–2.40] | 0.497 |
| HIV-specific risk factors|             |        |              |         |
| Exposure to older generation ART* | 2.35 [1.62–3.41] | <0.001 | 2.14 [1.24–3.71] | 0.006 |
| Duration of ART, per 5 years* | 1.38 [1.20–1.59] | <0.001 | 1.33 (0.99–1.79) | 0.054 |
| Time with HIV, per 5 years | 1.26 [1.14–1.39] | <0.001 | 1.19 (1.04–1.35) | 0.009 |
| CD4+ count, per 100 cells/µL | 1.00 [1.00–1.00] | 0.285 | 1.00 [1.00–1.00] | 0.333 |
| CD4+ nadir < 200 cells/µL | 1.69 [1.17–2.43] | 0.005 | 1.56 [1.02–2.38] | 0.038 |
| CD4+/CD8+ ratio, per 0.1 change in ratio | 0.79 [0.53–1.17] | 0.237 | 0.81 [0.53–1.24] | 0.326 |
| Previous AIDS defining condition | 1.61 [1.04–2.51] | 0.033 | 1.39 [0.83–2.30] | 0.209 |

*Calculated using our adjusted model, further adjusting for time with HIV

**Adjusted OR calculated using logistic regression in a model adjusted for age, sex, BMI, smoking status, and origin.**
abdominal obesity and insulin resistance was stronger in PLWH with prior exposure to older generation ART. This may suggest that the alterations of adipose tissue in PLWH exposed to older generation ART increase the effect of abdominal obesity on insulin resistance. In addition to older generation ART, CD4⁺ nadir < 200 cells/µL was associated with insulin resistance. This finding is consistent with other studies reporting lower CD4⁺ nadir to be associated with an increased risk of T2DM [2, 22]. Furthermore, both insulin resistance and prior immunodeficiency have been associated with cardiovascular comorbidity in PLWH [23].

There were limitations to this study. First, the study is cross-sectional which prevents us from drawing any conclusions regarding causality. Second, since there is no standardized cut-off value for insulin resistance the clinically significant insulin resistance is unknown. Third, we could not compare insulin resistance in PLWH to insulin resistance in uninfected controls because we did not have access to a control population with fasting blood samples. The strengths of the study include the large cohort of well-treated PLWH and the use of fasting blood samples to define insulin resistance.

Conclusions
In conclusion, in well-treated PLWH with absence of chronic hepatitis B or C infection, insulin resistance was associated with abdominal obesity, exposure to older generation ART, and CD4⁺ nadir < 200 cells/µL. This may suggest that insulin resistance in PLWH is associated with both prior immunodeficiency and metabolic changes due to exposure to older generation ART. Furthermore, the association between abdominal obesity and insulin resistance was stronger in PLWH with exposure to older generation ART than in PLWH without exposure to these drugs, suggesting older generation ART to have long-lasting effects on abdominal adipose tissue related to insulin resistance. This suggests that special attention on blood glucose in these patients could be beneficial.

Abbreviations
aOR: Adjusted OR; ART: Antiretroviral therapy; COCOMO Study: Copenhagen Comorbidity in HIV Infection Study; GLUT4: Glucose transporter 4; HDL-C: High-density lipoprotein cholesterol; HOMA: Homeostasis model assessment; IQR: Interquartile range; LDL-C: Low-density lipoprotein cholesterol; PLWH: People living with HIV; T2DM: Type 2 diabetes mellitus.

Acknowledgements
We thank all the study subjects for their participation. We thank the staff at the Departments of Infectious Diseases at Rigshospitalet and Amager and Hvidovre Hospital for their dedicated participation. Data from the manuscript have previously been presented as an e-poster at the European AIDS conference 2021 (London, October 27th–30rd 2021).

Author contributions
JH was responsible for concept, statistical analyses, and drafted the manuscript. MHS and MG were responsible for concept, statistical analysis and edited the manuscript. AMRJ and HS were responsible for concept and edited the manuscript. JG, TB and SDN were responsible for concept, data collection and edited the manuscript. All authors read and approved the final manuscript.

Funding
The COCOMO 2-year follow-up was supported by an unrestricted research grant from Gilead Sciences, Inc, Novo-Nordisk Foundation and Rigshospitalet Research Council.

Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Danish legislation does not allow the dataset to be freely available.

Declarations
Ethics approval and consent to participate
Ethical approval was obtained by the Regional Ethics Committee of Copenhagen (H-8-2014-004). The study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
JH reports grant from Novo Nordisk Foundation and Rigshospitalet Research Council. MHS, MG, AMRJ and JG reports no conflicts of interest. TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, personal fees from Astra Zeneca, personal fees from Janssen, grants from Lundbeck Foundation, grants from Kaug Hansen Foundation, personal fees from PentoBase ApS, grants from Erik and Susanna Olesen’s Charitable Fund, outside the submitted work. HS reports Steno Collaborative Grant, Novo Nordisk Foundation and advisory board activity for Novo Nordisk. S.D.N. has received unrestricted research grants from Novo Nordisk Foundation, Lundbeck Foundation, Rigshospitalet Research Council. Travelling grants from Gilead. Advisory board activity for Gilead and MSD, all unrelated to this manuscript. All other authors report no conflicts of interest.

Author details
1 Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. 2 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3 Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark. 4 Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.

Received: 25 January 2022 Accepted: 18 May 2022
Published online: 28 May 2022

References
1. Smitt M, Brinkman K, Geerlings S, Smitt C, Thyagarajan K, van Sighem AV, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–8.
2. Brown TT, Cole SR, Li K, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study [published correction appears in Arch Intern Med. 2005 Nov 28;165(21):2541]. Arch Intern Med. 2005;165(10):1179–84.
3. Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals
compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care. 2017;5(1):e000304.

4. Høgh J, Gelpi M, Skovsgaard MH, Afzal S, Nordsgaard BG, Gerstoft J, et al. HIV infection is associated with type 2 diabetes mellitus. J Acquir Immune Defic Syndr. 2021;88(4):e52–5.

5. Pedro MN, Rocha GZ, Guadagnini D, Santos A, Magro DO, Assalini HB, et al. Insulin resistance in HIV-patients: causes and consequences. Front Endocrinol. 2018;9:514.

6. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs. 2002;16(2):17–23.

7. Westphal SA. Obesity, abdominal obesity, and insulin resistance. Clin Cornerstone. 2008;9(1):23–31.

8. Rönnermaa T, Koskenuvu M, Marniemi J, Koivunen T, Sajantila A, Rissanen R, et al. Glucose metabolism in identical twins discordant for obesity: The critical role of visceral fat 1. J Clin Endocrinol Metab. 1997;82(2):383–7.

9. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care. 2008;31(6):1224–9.

10. Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: A Danish nationwide population-based cohort study. PLoS ONE. 2012;7(9):e44575.

11. Gelpi M, Afzal S, Fuchs A, Lundgren J, Knudsen AD, Drivsholm N, et al. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. AIDS. 2019;33(4):675–83.

12. Gelpi M, Knudsen AD, Larsen KB, Mocroft A, Lebech AM, Lindegaard B, et al. Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. BMC Infect Dis. 2019;19(1):708.

13. Ronit A, Haissman J, Kirkegaard-Klitbo DM, Kristensen TS, Lebech AM, Benfield T, et al. Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. BMC Infect Dis. 2016;16(1):713.

14. Department of Nutrition for Health and Development - World Health Organization. Waist circumference and waist-hip ratio—Report of a WHO Expert Consultation. Geneva: World Health Organization, 2008.

15. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA J Am Med Assoc. 2014;311(5):507–20.

16. Matthews DE, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

17. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol - Endocrinol Metab. 2008;294(1):e15–26.

18. Gelpi M, Afzal S, Lundgren J, Ronit A, Roen A, Mocroft A, et al. Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglyceridemia, but not of hypertension, in people living with human immunodeficiency virus (HIV): results from the Copenhagen comorbidity in HIV infection study. Clin Infect Dis. 2018;67(4):579–86.

19. Wu WC, Wei JN, Chen SC, Fan KC, Lin CH, Yang CY, et al. Progression of insulin resistance: a link between risk factors and the incidence of diabetes. Diabetes Res Clin Pract. 2020;161:108050.

20. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002;16(6):859–63.

21. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275(27):20251–4.

22. Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, et al. Association of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infect Dis. 2017;17(1):43.

23. Berneer M, Post WS, Haberlen SA, Zhang L, Pallella FJ, Jacobson LP, et al. Comparison of insulin resistance to coronary atherosclerosis in human immunodeficiency virus infected and uninfected men (from the Multicenter AIDS Cohort Study). Am J Cardiol. 2016;117(6):993–1000.